Fabio Pellegrini
Overview
Explore the profile of Fabio Pellegrini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
5091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hersh C, Sun Z, Conway D, Sotirchos E, Fitzgerald K, Hua L, et al.
Mult Scler Relat Disord
. 2024 Sep;
91:105847.
PMID: 39260226
Background: Two-stage models of heterogenous treatment effects (HTE) may advance personalized medicine in multiple sclerosis (MS). Brain atrophy is a relatively objective outcome measure that has strong relationships to MS...
2.
Chalkou K, Hamza T, Benkert P, Kuhle J, Zecca C, Simoneau G, et al.
Res Synth Methods
. 2024 Mar;
15(4):641-656.
PMID: 38501273
Some patients benefit from a treatment while others may do so less or do not benefit at all. We have previously developed a two-stage network meta-regression prediction model that synthesized...
3.
Simoneau G, Mitroiu M, Debray T, Wei W, Wijn S, Magalhaes J, et al.
J Comp Eff Res
. 2024 Jan;
13(2):e230089.
PMID: 38261336
Comparative effectiveness research using real-world data often involves pairwise propensity score matching to adjust for confounding bias. We show that corresponding treatment effect estimates may have limited external validity, and...
4.
Spelman T, Magyari M, Butzkueven H, van der Walt A, Vukusic S, Trojano M, et al.
Front Neurol
. 2024 Jan;
14:1274194.
PMID: 38187157
Background: Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors...
5.
Jiang X, Simoneau G, Zuercher M, Heer Y, van Hoevell P, Harrington A, et al.
Mult Scler J Exp Transl Clin
. 2023 Aug;
9(3):20552173231194353.
PMID: 37641619
Background: Multiple sclerosis (MS) comparative effectiveness research needs to go beyond average treatment effects (ATEs) and post-host subgroup analyses. Objective: This retrospective study assessed overall and patient-specific effects of dimethyl...
6.
Debray T, Simoneau G, Copetti M, Platt R, Shen C, Pellegrini F, et al.
Stat Methods Med Res
. 2023 Jun;
32(7):1284-1299.
PMID: 37303120
Real-world data sources offer opportunities to compare the effectiveness of treatments in practical clinical settings. However, relevant outcomes are often recorded selectively and collected at irregular measurement times. It is...
7.
Hamza T, Chalkou K, Pellegrini F, Kuhle J, Benkert P, Lorscheider J, et al.
Res Synth Methods
. 2023 Jan;
14(2):283-300.
PMID: 36625736
In network meta-analysis (NMA), we synthesize all relevant evidence about health outcomes with competing treatments. The evidence may come from randomized clinical trials (RCT) or non-randomized studies (NRS) as individual...
8.
Chalkou K, Vickers A, Pellegrini F, Manca A, Salanti G
Med Decis Making
. 2022 Dec;
43(3):337-349.
PMID: 36511470
Background: Decision curve analysis can be used to determine whether a personalized model for treatment benefit would lead to better clinical decisions. Decision curve analysis methods have been described to...
9.
Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, et al.
J Neurol Neurosurg Psychiatry
. 2022 Sep;
94(1):23-30.
PMID: 36171104
Background: Over the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on...
10.
Simoneau G, Jiang X, Rollot F, Tian L, Copetti M, Guery M, et al.
Mult Scler J Exp Transl Clin
. 2022 Aug;
8(3):20552173221116591.
PMID: 35959484
Background: Comparing real-world effectiveness and tolerability of therapies for relapsing-remitting multiple sclerosis is increasingly important, though average treatment effects fail to capture possible treatment effect heterogeneity. With the clinical course...